Alivus Life Sciences Limited has informed the Exchange about Investor Presentation
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences reported Q4 FY25 revenue from operations of ₹6,496 Mn, up 21.1% year-on-year, driven by strong growth in both Generic API (22.6% YoY) and CDMO (22.6% YoY, 44.4% QoQ) segments. Full-year FY25 revenue grew 4.5% to ₹23,869 Mn, with EBITDA margins holding steady at 30% despite the loss of PLI benefits from the prior year. Q4 EBITDA margins expanded 520 basis points YoY to 32.1%, while PAT for the quarter rose 44.9% YoY to ₹1,419 Mn. The company generated ₹2,328 Mn in free cash flow, building cash reserves to ₹5,487 Mn. Management highlighted capacity expansion plans across Ankleshwar, Dahej, and a new greenfield plant at Solapur, targeting total reactor capacity growth from 1,424 KL in FY25 to 2,650 KL by FY28. The 5th CDMO project is expected to commercialize by H2 FY26.
Margin expansion in Q4 along with strong cash generation and a clear capacity expansion roadmap should support investor confidence. Steady margins without PLI benefits and growing CDMO pipeline signal business resilience, though working capital days increased to 192.